A potent carbonic anhydrase inhibitor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Brinzolamide

Item No. 11660

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4R-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-1,1-dioxide-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide
CAS Number
138890-62-7
Synonyms
  • AL 4862
Molecular Formula
C12H21N3O5S3
Formula Weight
383.5
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlDMSO:PBS(pH 7.2) (1:2): 0.3 mg/ml
λmax
253 nm
SMILES
O=S(C1=CC2=C(S1)S(N(CCCOC)C[C@@H]2NCC)(=O)=O)(N)=O
InChi Code
InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1
InChi Key
HCRKCZRJWPKOAR-JTQLQIEISA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 mg

    $37

    Add

    25 mg

    $73

    Add

    50 mg

    $136

    Add

    100 mg

    $216

    Add
    Product Description

    Brinzolamide is a potent inhibitor of carbonic anhydrase II (CAII) and CAIV (IC50s = 3.19 and 45.3 nM, respectively).1 It is selective for CAII and CAIV over CAI (IC50 = ~1,365 nM). Brinzolamide (30 mg/kg) reduces intestinal charcoal meal progression by 44% and prolongs pentobarbital sodium-induced sleep time by 35% in mice. Topical administration of brinzolamide (0.25, 0.5, and 1 mg/eye) reduces intraocular pressure (IOP) in a rabbit model of spontaneous ocular hypertension. It also reduces IOP in a cynomolgus monkey model of argon laser trabeculoplasty-induced ocular hypertension. Formulations containing brinzolamide have been used in the treatment of glaucoma and ocular hypertension.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. DeSantis, L. Preclinical overview of brinzolamide. Surv. Ophthalmol. 44(Suppl. 2), S119-S129 (2000).